Physician profile
William Meng
NPI 1215380670
$3,490.15
in general payments reported to CMS, 2019-2025
12 companies · $62.08 in 2025
The $62.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $712 · 2021: $677 · 2022: $198 · 2023: $132 · 2024: $1,463 · 2025: $62.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,342 · Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,342.46 |
| Food and Beverage | $315.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,591.77 | 2019-2022 | |
| Intuitive Surgical, INC. | $1,474.93 | 2023-2024 | Da Vinci Surgical System |
| Pulmonx Corporation | $120.70 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Medtronic, INC. | $62.08 | 2025 | Illumisite, Superlock |
| Astrazeneca Pharmaceuticals Lp | $59.74 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $44.15 | 2020 | |
| Olympus Corporation of The Americas | $43.86 | 2022 | |
| Pfizer INC. | $27.71 | 2020-2021 | |
| Mylan Specialty L.P. | $20.62 | 2020 | |
| Biomerieux INC | $15.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.